Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00510718 | A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | completed | Phase 1 | 140 | PfizerINDUSTRY | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01585246 | Saw Palmetto: Symptom Management for Men During Radiation Therapy | completed | Phase 1 / Phase 2 | 48 | Michigan State UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid |
| completed |
| Phase 1 |
| 33 |
| OPKO Health, Inc.INDUSTRY |
| 1 |
| Sep 27, 2019 |
| clinicaltrials |
| NCT04107142 | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | unknown | Phase 1 | 10 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT00124917 | Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer | terminated | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2019 | clinicaltrials |
| NCT02324998 | Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy(CaNCaP03) | completed | Phase 1 | 20 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT02262910 | Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 35 | Aptevo TherapeuticsINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT01083368 | Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy | completed | Phase 1 / Phase 2 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01028885 | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00669162 | Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Kansas Medical CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02796898 | Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 23 | Tyme, IncINDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02064608 | Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer(CaNCaP02) | completed | Phase 1 | 23 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT02182622 | LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | withdrawn | Phase 1 | 0 | Martin GutierrezOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01565928 | Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer | completed | Phase 1 | 23 | PfizerINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
| NCT00348595 | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03030885 | Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT02111187 | A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer(LDE225) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00311623 | Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02507427 | Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study) | completed | Phase 1 / Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02202447 | Phase 1 of EC1169 In Patients With Recurrent MCRPC | completed | Phase 1 | 40 | EndocyteINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01741753 | BKM120+Abiraterone Acetate for Metastatic CRPC | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02478125 | Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01417182 | Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer | completed | Phase 1 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT00790374 | BN83495 in Prostate Cancer(STX64PC) | completed | Phase 1 | 17 | IpsenINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT03450109 | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer | completed | Phase 1 | 19 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01262664 | A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02655952 | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients | completed | Phase 1 | 17 | WntResearch ABINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | completed | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00082732 | Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00038194 | Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00379561 | PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer | completed | Phase 1 | 24 | Sophiris Bio CorpINDUSTRY | 1 | Oct 29, 2018 | clinicaltrials |
| NCT02234921 | Pilot Study of DRibble Vaccine for Prostate Cancer Patients(DRibble) | completed | Phase 1 | 3 | UbiVacINDUSTRY | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01144897 | PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy | completed | Phase 1 | 5 | Daniel VaenaOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01497925 | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | completed | Phase 1 | 43 | Polaris GroupINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02058680 | Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients(PSA) | unknown | Phase 1 | 48 | OncBioMune PharmaceuticalsOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01513733 | The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer(CATCH) | completed | Phase 1 | 25 | Andrew J. Armstrong, MDOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01303705 | Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01496157 | Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 3, 2019source: clinicaltrials